Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00410761 · OUTCOME

Progression-Free Survival(PFS)

An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer · Source last updated 2025-09-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
RECIST tumour assessments were performed at screening (within 3 weeks before date of randomisation), then once every 12 weeks up to and including discontinuation of blinded study treatment, unless patients had withdrawn consent.

What was measured

Median time to progression (months) from randomisation until objective disease progression (determined by RECIST assessments) or death (by any cause in the absence of objective progression) provided death is within 3 months from the last evaluable RECIST assessment. Values here are estimated (from a Weibull model) as the medians were not met.

Groups in this outcome

Vandetanib 300 mg

Vandetanib (300 mg daily)

Placebo

Placebo daily

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Vandetanib 300 mg231
Placebo100

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Vandetanib 300 mg30.5Not reportedNANAPFS is a time to event endpoint and because the medians were not met in this study there is no appropriate measure of dispersion of the median
Placebo19.2Not reportedNANAPFS is a time to event endpoint and because the medians were not met in this study there is no appropriate measure of dispersion of the median
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        PFS is a time to event endpoint and because the medians were not met in this study there is no appropriate measure of dispersion of the median
        group Id
        OG000
        lower Limit
        NA
        upper Limit
        NA
        value
        30.5
      2. comment
        PFS is a time to event endpoint and because the medians were not met in this study there is no appropriate measure of dispersion of the median
        group Id
        OG001
        lower Limit
        NA
        upper Limit
        NA
        value
        19.2
denoms
  1. counts
    1. group Id
      OG000
      value
      231
    2. group Id
      OG001
      value
      100
    units
    Participants
description
Median time to progression (months) from randomisation until objective disease progression (determined by RECIST assessments) or death (by any cause in the absence of objective progression) provided death is within 3 months from the last evaluable RECIST assessment. Values here are estimated (from a Weibull model) as the medians were not met.
dispersion Type
95% Confidence Interval
groups
  1. description
    Vandetanib (300 mg daily)
    id
    OG000
    title
    Vandetanib 300 mg
  2. description
    Placebo daily
    id
    OG001
    title
    Placebo
param Type
MEDIAN
reporting Status
POSTED
time Frame
RECIST tumour assessments were performed at screening (within 3 weeks before date of randomisation), then once every 12 weeks up to and including discontinuation of blinded study treatment, unless patients had withdrawn consent.
title
Progression-Free Survival(PFS)
type
PRIMARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice